Two Johns Hopkins research teams have received technology development grants totaling approximately $200,000 through the Louis B. Thalheimer Fund for Translational Research.
A total of 14 researchers applied for the latest funding round. Finalists pitched their proposals virtually in late May to an outside panel of independent researchers and investors, innovation executives and venture investors.
Established through a $5.4 million gift from businessman and philanthropist Louis B. Thalheimer, the fund provides seed funding for proof-of-concept and validation studies of Johns Hopkins technologies.
Since 2016, the Thalheimer Fund has awarded more than $1.7 million to 20 projects at Johns Hopkins. Grants range from $25,000 to $100,000 and all recipients have formally reported their inventions to Johns Hopkins Technology Ventures (JHTV).
Previous Thalheimer winners are developing a faster and more accurate way to diagnose epilepsy; an oral therapy for patients suffering from inflammatory bowel disease; and a longer-lasting treatment for wrinkles and migraines, among other technologies.
This year’s grantees are:
Urinfo: Holographic Urine Monitoring to Prevent Catheter-Associated Urinary Tract Infections
Principal investigator: Nicholas J. Durr, assistant professor in the Department of Biomedical Engineering
The pitch: Real-time patient monitoring for early signs of potential infection
Catheter-associated urinary tract infections (CA-UTIs) are the most common hospital-based infections. A significant risk factor is prolonged used of a catheter, and nearly 80% of the 500,000 annual cases are thought to be preventable with timely intervention.
The current approach to managing CA-UTIs is mostly reactive, monitoring for symptoms followed by diagnostic confirmation. Durr and his collaborators have invented a lens-free imaging device that can provide continuous, noninvasive analysis of urine to with the potential to detect early signs of CA-UTI.
A flow chamber sits between the catheter and urine bag that is continually imaged, from which the urine’s bacterial load is determined through an algorithm. If the load surpasses a predefined threshold or displays a worrisome trend, the clinician is alerted. Flow chambers would be changed for each patient, while the rest of the system would be reusable.
JHTV is pursuing patent protection for the technology. The team has developed a benchtop prototype of the system and part of the Thalheimer funding will go toward developing a bedside prototype. They also will use the grant to collect initial data to prepare a federal Small Business Innovation Research grant application.
Cytoplasmic Transfer Cell Therapy for Vision Repair in Retinitis Pigmentosa
Principal investigator: Mandeep S. Singh, assistant professor of ophthalmology and genetic medicine at the Johns Hopkins Wilmer Eye Institute
The pitch: A novel way to treat multiple inherited retinal diseases at once.
Inherited retinal diseases (IRDs) cause vision loss in approximately one in 4,000 people and are caused by a mutation in any one of about 300 genes expressed in photoreceptor cells of the retina. Gene therapies are in development to treat more than 25 individual IRD gene mutations. But Singh, working with Robert Johnston, Ph.D., an associate professor in the Department of Biology at The Johns Hopkins University, is developing a new treatment modality, cytoplasmic transfer cell (CTC) therapy, that has the potential to treat the majority of IRDs with one off-the-shelf product.
CTC therapy involves generating differentiated photoreceptor cells from human pluripotent stem cells, cells that can be developed into any type of human cell, that are then administered to patients. Early observations suggest CTC treatment may permanently restore vision with just one treatment. The team is initially focusing on treating autosomal recessive retinitis pigmentosa (ARRP), a progressive hereditary disorder which accounts for 35% of IRDs.
JHTV is pursuing patent protection for the technology. Singh is planning to form a startup around the technology and has met potential investors with the help of Sashank Reddy, JHTV’s medical director. The Thalheimer funding will go toward hiring staffers to help culture CTC cells and continue testing.